No Data
Is Chimerix (NASDAQ:CMRX) In A Good Position To Invest In Growth?
H.C. Wainwright Maintains Chimerix(CMRX.US) With Buy Rating, Maintains Target Price $11
Express News | HC Wainwright & Co. Reiterates Buy on Chimerix, Maintains $11 Price Target
Chimerix Analyst Ratings
Edward White's Buy Rating on Chimerix Driven by Promising Clinical Data and Strategic NDA Plans
CervoMed CRVO Phase 2b Fails; Chimerix SNDA Application